Zymeworks(ZYME) ZACKS·2025-03-05 23:16Core Points - Zymeworks Inc. reported a quarterly loss of $0.31 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.32, but worse than the loss of $0.20 per share from the previous year, indicating a 55% increase in loss year-over-year [1] - The company posted revenues of $31.03 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 15.54%, and showing a significant increase from $16.93 million in the same quarter last year [2] - Zymeworks shares have declined approximately 12.9% since the beginning of the year, contrasting with the S&P 500's decline of 1.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.43 on revenues of $16.67 million, and for the current fiscal year, it is -$1.64 on revenues of $91.31 million [7] - The estimate revisions trend for Zymeworks is mixed, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Zymeworks belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]